VFEND 200 MG — DIN 02256479
VORICONAZOLE : 200 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is VFEND?
VFEND 200 MG contains VORICONAZOLE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02256479, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Nov-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VFEND used for?
VFEND (voriconazole) is indicated for: • Invasive aspergillosis • Candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Voriconazole cost around the world?
Voriconazole is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 23 | 30 | SAR███.██ |
| United States | acquisition | 3 | 29 | USD███.██ |
| Czechia | max producer price (ex-factory) | 10 | 18 | CZK███.██ |
| Australia | ex-manufacturer | 4 | 14 | AUD███.██ |
| South Africa | single exit price | 14 | 14 | ZAR███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 6 | 10 | EUR███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| United Arab Emirates | public | 7 | 7 | AED███.██ |
| Bahrain | retail (max) | 3 | 5 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
155 pack listings across 96 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Voriconazole pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Voriconazole in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Voriconazole, across 27 DINs, of which 11 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 4 | 4 | VFEND | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP VORICONAZOLE, VORICONAZOLE FOR INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ VORICONAZOLE, VORICONAZOLE FOR INJECTION | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | VORICONAZOLE FOR INJECTION | Sourceable in Canada |
| AURO PHARMA INC | 3 | 0 | AURO-VORICONAZOLE, VORICONAZOLE FOR INJECTION | No marketed DIN |
| ACCORD HEALTHCARE INC | 2 | 0 | ACH-VORICONAZOLE | No marketed DIN |
| APOTEX INC | 2 | 0 | APO-VORICONAZOLE | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-VORICONAZOLE | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | TEVA-VORICONAZOLE | No marketed DIN |
| FORMATIVE PHARMA INC. | 1 | 0 | VORICONAZOLE FOR INJECTION | No marketed DIN |
| PHARMARIS CANADA INC | 1 | 0 | VORICONAZOLE FOR INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-VORICONAZOLE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets 50 mg and 200 mg, Oral; 200 mg / Vial for Injection; Powder for Oral Suspension 3 g / Bottle |
| Storage | The shelf-life of the reconstituted suspension is 14 days at 15° to 30°C. Do not refrigerate or freeze. Keep the container tightly closed. Once reconstituted, VFEND I.V. for Injection should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2° to 8°C (36° to 46°F). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Voriconazole |
|---|---|
| ATC code | J02AC03 |
| AHFS class | 08:14.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02256479 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2256479 |
| Brand name | VFEND |
| Generic / active ingredient | VORICONAZOLE : 200 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | J02AC03 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J02AC |
| Current status | MARKETED |
| Status date | 12-Nov-2004 |
| Original market date | 2004-11-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Voriconazole in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
11 of 27 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP VORICONAZOLE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02525798 |
| JAMP VORICONAZOLE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02525771 |
| SANDOZ VORICONAZOLE | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02399253 |
| SANDOZ VORICONAZOLE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02399245 |
| VFEND | 200 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | 02279991 |
| VFEND | 50 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02256460 |
| VFEND | 200 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02256487 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02477696 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02493829 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02381966 |
2 · Same class — other molecules in ATC J02AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fluconazole | ACT FLUCONAZOLE · AG-FLUCONAZOLE · APO-FLUCONAZOLE · APO-FLUCONAZOLE-150 · +35 more | 71 | 29 | Yes |
| Voriconazole | ACH-VORICONAZOLE · APO-VORICONAZOLE · AURO-VORICONAZOLE · JAMP VORICONAZOLE · +7 more | 27 | 11 | Yes |
| Posaconazole | APO-POSACONAZOLE · GLN-POSACONAZOLE · JAMP POSACONAZOLE · MINT-POSACONAZOLE · +3 more | 9 | 8 | Yes |
| Itraconazole | JAMP ITRACONAZOLE ORAL SOLUTION · MINT-ITRACONAZOLE · ODAN ITRACONAZOLE · SPORANOX | 5 | 3 | Yes |
| Isavuconazole | CRESEMBA | 3 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J02AX | Anidulafungin · Caspofungin · Micafungin | 25 | 12 |
| J02AA | Amphotericin B | 7 | 2 |
| J02AB | Ketoconazole | 5 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VFEND called?
The same molecule, Voriconazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Voriconazole Sandoz | Latin | Australia |
| Vttack | Latin | Australia |
| Vzole | Latin | Australia |
| Voricet | Latin | Bahrain, Saudi Arabia |
| Vecanzol | Latin | Saudi Arabia |
| Vodar | Latin | Saudi Arabia |
| VORICONAZOLE ACCORD | Latin | Czechia |
| VORICONAZOLE OLIKLA | Latin | Czechia |
| VORICONAZOLE SANEXCEL | Latin | Czechia |
| VORICONAZOLE TEVA | Latin | Czechia |
| VORIKONAZOL VIATRIS | Latin | Czechia |
| Voconza | Latin | Saudi Arabia |
| VORIC | Latin | Saudi Arabia |
| Vorican | Latin | Saudi Arabia |
| VORICONAZOLE | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.